Decorin and Colchicine as Potential Treatments for Post-Haemorrhagic Ventricular Dilatation in a Neonatal Rat Model

Background: Post-haemorrhagic ventricular dilatation (PHVD) after intraventricular haemorrhage (IVH) remains a significant problem in preterm infants. Due to serious disadvantages of ventriculoperitoneal shunt dependence, there is an urgent need for non-surgical interventions. Considerable experimental and clinical evidence implicates transforming growth factor β (TGFβ) in the pathogenesis of PHVD. Colchicine and decorin are both compounds with anti-TGFβ properties. The former downregulates TGFβ production and is in clinical use for another fibrotic disease, and the latter inactivates TGFβ. Objectives: We hypothesized that administration of decorin or colchicine, which both have anti-TGFβ properties, would reduce ventricular dilatation in a model of PHVD. Methods: 142 rat pups underwent intraventricular blood injection on postnatal days (PN) 7 and 8. Sixty-nine pups were randomized to colchicine 20 and 50 µg/kg/day or water by gavage for 13 days. Seventy were randomized to decorin 4 mg/kg or saline by intraventricular injection on PN8 and PN13. At PN21, the ventricular area was measured on coronal brain sections. Negative geotaxis was tested at PN14 in controls and in the decorin study group. Results: Ventricular size was not different between animals receiving either drug or water/saline. Intraventricular blood impaired neuromotor performance, but decorin had no effect. Conclusion: Two drugs that block TGFβ by different mechanisms do not reduce ventricular dilatation in this model. Together with our previous work on losartan and pirfenidone, we conclude that blocking TGFβ alone does not prevent the development of PHVD.

[1]  A. Whitelaw,et al.  Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model? , 2008, Acta paediatrica.

[2]  A. Whitelaw,et al.  Randomized Clinical Trial of Prevention of Hydrocephalus After Intraventricular Hemorrhage in Preterm Infants: Brain-Washing Versus Tapping Fluid , 2007, Pediatrics.

[3]  A. Tamas,et al.  Neurological reflexes and early motor behavior in rats subjected to neonatal hypoxic–ischemic injury , 2005, Behavioural Brain Research.

[4]  S. Love,et al.  Transforming growth factor‐βs in a rat model of neonatal posthaemorrhagic hydrocephalus , 2004, Neuropathology and applied neurobiology.

[5]  M. Weller,et al.  Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model , 2004, Cancer Gene Therapy.

[6]  C. Schaller,et al.  Vascular Endothelial Growth Factor and Transforming Growth Factor-β1 Are Highly Expressed in the Cerebrospinal Fluid of Premature Infants with Posthemorrhagic Hydrocephalus , 2004, Pediatric Research.

[7]  Tony Wyss-Coray,et al.  Insights into the Pathogenesis of Hydrocephalus from Transgenic and Experimental Animal Models , 2004, Brain pathology.

[8]  S. Davies,et al.  Decorin suppresses neurocan, brevican, phosphacan and NG2 expression and promotes axon growth across adult rat spinal cord injuries , 2004, The European journal of neuroscience.

[9]  K. Kang,et al.  Effects of colchicine on liver functions of cirrhotic rats: beneficial effects result from stellate cell inactivation and inhibition of TGF beta1 expression. , 2004, Chemico-biological interactions.

[10]  C. Rousselle,et al.  In Vivo Saturation of the Transport of Vinblastine and Colchicine by P-Glycoprotein at the Rat Blood–Brain Barrier , 2003, Pharmaceutical Research.

[11]  F. Yalçınkaya,et al.  Colchicine treatment in children with familial Mediterranean fever , 2003, Clinical Rheumatology.

[12]  S. Love,et al.  Posthemorrhagic Ventricular Dilation in the Neonate: Development and Characterization of a Rat Model , 2003, Journal of neuropathology and experimental neurology.

[13]  I. Roberts,et al.  Inhibition of chronic vascular rejection by donor-specific blood transfusion is associated with a reduction in transforming growth factor-&bgr;1 expression1 , 2002, Transplantation.

[14]  A. Logan,et al.  Expression of TGFβ2 but Not TGFβ1 Correlates with the Deposition of Scar Tissue in the Lesioned Spinal Cord , 2002, Molecular and Cellular Neuroscience.

[15]  D. Elbourne,et al.  Randomized, controlled trial of acetazolamide and furosemide in posthemorrhagic ventricular dilation in infancy: follow-up at 1 year. , 2001, Pediatrics.

[16]  Johnny Huard,et al.  The Use of an Antifibrosis Agent to Improve Muscle Recovery after Laceration * , 2001, The American journal of sports medicine.

[17]  M. Berry,et al.  Transforming Growth Factor-β1 in the Cerebrospinal Fluid of Patients with Subarachnoid Hemorrhage: Titers Derived from Exogenous and Endogenous Sources , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  P. Scheuer,et al.  Multicentre randomized placebo‐controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis , 2000, Alimentary pharmacology & therapeutics.

[19]  A. Whitelaw,et al.  Transforming Growth Factor-β1: A Possible Signal Molecule for Posthemorrhagic Hydrocephalus? , 1999, Pediatric Research.

[20]  M. Berry,et al.  Decorin Attenuates Gliotic Scar Formation in the Rat Cerebral Hemisphere , 1999, Experimental Neurology.

[21]  K. Chung,et al.  Regulation of type I collagen and interstitial collagenase mRNA expression in human dermal fibroblasts by colchicine and D-penicillamine. , 1999, Yonsei medical journal.

[22]  Georg W. Kreutzberg,et al.  Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function , 1999, Brain Research Reviews.

[23]  M. Berry,et al.  Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor‐β2 , 1999, The European journal of neuroscience.

[24]  Tsuyoshi Tada,et al.  A murine model of communicating hydrocephalus: Role of TGF-β1 , 1997, Journal of Clinical Neuroscience.

[25]  A. Messing,et al.  Overexpression of TGF‐β1 in the Central Nervous System of Transgenic Mice Results in Hydrocephalus , 1995, Journal of neuropathology and experimental neurology.

[26]  D. Elbourne,et al.  Randomised trial of early tapping in neonatal posthaemorrhagic ventricular dilatation: results at 30 months , 1994, Archives of disease in childhood. Fetal and neonatal edition.

[27]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[28]  E. Ruoslahti,et al.  Negative regulation of transforming growth factor-β by the proteoglycan decorin , 1990, Nature.

[29]  Ventriculomegaly Trial Group,et al.  Randomised trial of early tapping in neonatal posthaemorrhagic ventricular dilatation. Ventriculomegaly Trial Group. , 1990, Archives of disease in childhood.

[30]  Joseph J. Volpe,et al.  Intracranial Hemorrhage: Germinal Matrix–Intraventricular Hemorrhage of the Premature Infant , 2008 .

[31]  M. Berry,et al.  Expression of TGFbeta2 but not TGFbeta1 correlates with the deposition of scar tissue in the lesioned spinal cord. , 2002, Molecular and cellular neurosciences.

[32]  S. Kobayashi,et al.  A murine model of communicating hydrocephalus: Role of TGF-beta1. , 1997, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.

[33]  E. Ruoslahti,et al.  Negative regulation of transforming growth factor-beta by the proteoglycan decorin. , 1990, Nature.

[34]  J. Larroche Post-haemorrhagic hydrocephalus in infancy. Anatomical study. , 1972, Biology of the neonate.